Patents Assigned to Transgenic Inc.
-
Publication number: 20220340926Abstract: Provided are a donor vector having an exon-humanized gene in which only exon nucleotide sequences of a mouse gene are replaced with human exon nucleotide sequences, an ES cell in which a mouse endogenous gene is replaced with the donor vector, and a mouse crated by using the ES cell.Type: ApplicationFiled: May 27, 2019Publication date: October 27, 2022Applicant: TRANSGENIC INC.Inventors: Kenichi YAMAMURA, Zhenghua LI
-
Patent number: 10765094Abstract: The present invention provides a method for detection of an inflammatory reaction, which comprises using a transformant or transgenic non-human animal transfected with a vector comprising a promoter for a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, a gene encoding the inflammatory cytokine, and a gene encoding a proteolytic signal sequence to thereby detect an inflammatory reaction induced upon inflammatory stimulation in the transformant or in the transgenic non-human animal.Type: GrantFiled: July 31, 2014Date of Patent: September 8, 2020Assignees: TRANSGENIC INC., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITYInventors: Kenichi Yamamura, Takao Iwawaki, Daisuke Oikawa, Tomoo Ishikawa
-
Publication number: 20180360006Abstract: The present invention provides embryonic stem cells obtained from an embryo of a mouse engineered to replace all or some of domains in the mouse MHC class I molecule H2-D with domains from the human MHC class I molecule HLA-A by culture in the presence of a GSK3 inhibitor and an MEK inhibitor, as well as a mouse which is created with the use of these embryonic stem cells.Type: ApplicationFiled: June 18, 2015Publication date: December 20, 2018Applicant: TRANSGENIC INC.Inventors: Kenichi YAMAMURA, Zhenghua LI
-
Publication number: 20170215394Abstract: The present invention provides a method for detection of an inflammatory reaction, which comprises using a transformant or transgenic non-human animal transfected with a vector comprising a promoter for a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, a gene encoding the inflammatory cytokine, and a gene encoding a proteolytic signal sequence to thereby detect an inflammatory reaction induced upon inflammatory stimulation in the transformant or in the transgenic non-human animal.Type: ApplicationFiled: July 31, 2014Publication date: August 3, 2017Applicants: TRANSGENIC INC., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITYInventors: Kenichi YAMAMURA, Takao IWAWAKI, Daisuke OIKAWA, Tomoo ISHIKAWA
-
Patent number: 8883972Abstract: The present invention provides an antibody, which reacts with a FGA or FGA partial peptide in which a part of prolines in the molecule thereof are hydroxylated, and which does not react with an unmodified FGA or FGA partial peptide.Type: GrantFiled: February 12, 2009Date of Patent: November 11, 2014Assignees: Transgenic Inc., President, National Cancer CenterInventors: Hiroshi Nose, Tomoyo Hashiguchi, Masaya Ono, Tesshi Yamada, Setsuo Hirohashi
-
Patent number: 8722408Abstract: A trap vector containing a loxP sequence composed of inverted repeat sequence 1, a spacer sequence and inverted repeat sequence 2 in this order, the loxP sequence being a mutant loxP wherein a part of the inverted repeat sequence 1 or 2 is mutated.Type: GrantFiled: January 10, 2011Date of Patent: May 13, 2014Assignee: Transgenic Inc.Inventors: Ken-ichi Yamamura, Kimi Araki
-
Publication number: 20090202988Abstract: A trap vector containing a loxP sequence composed of inverted repeat sequence 1, a spacer sequence and inverted repeat sequence 2 in this order, the loxP sequence being a mutant loxP wherein a part of the inverted repeat sequence 1 or 2 is mutated.Type: ApplicationFiled: October 12, 2007Publication date: August 13, 2009Applicant: TRANSGENIC INC.Inventors: Ken-ichi Yamamura, Kimi Araki
-
Patent number: 7312075Abstract: A trap vector containing a loxP sequence composed of inverted repeat sequence 1, a spacer sequence and inverted repeat sequence 2 in this order, the loxP sequence being a mutant loxP wherein a part of the inverted repeat sequence 1 or 2 is mutated.Type: GrantFiled: May 2, 2000Date of Patent: December 25, 2007Assignee: Transgenic Inc.Inventors: Ken-ichi Yamamura, Kimi Araki
-
Patent number: 6441145Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: August 28, 1998Date of Patent: August 27, 2002Assignee: Genzyme Transgenics, Inc.Inventors: Paul DiTullio, Harry Meade, Edward S. Cole